Bristol-Myers Squibb Aktie 914188 / US1101221083
58.87
USD
0.64
USD
1.10%
22.11.2024
BTT
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Watchlist | |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Orderbuch | Analysen | |||||
| Historisch | ||||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
Bristol-Myers Squibb Dividenden Kalender
| Datum | Name | Rendite * | Dividende | Währung |
|---|---|---|---|---|
| 2023 | Bristol-Myers Squibb Co. | 4.50 | 2.31 | USD |
| 2022 | Bristol-Myers Squibb Co. | 3.04 | 2.19 | USD |
| 2021 | Bristol-Myers Squibb Co. | 3.22 | 2.01 | USD |
| 2020 | Bristol-Myers Squibb Co. | 2.97 | 1.84 | USD |
| 2019 | Bristol-Myers Squibb Co. | 2.62 | 1.68 | USD |
| 2018 | Bristol-Myers Squibb Co. | 3.10 | 1.61 | USD |
| 2017 | Bristol-Myers Squibb Co. | 2.56 | 1.57 | USD |
| 2016 | Bristol-Myers Squibb Co. | 2.62 | 1.53 | USD |
| 2015 | Bristol-Myers Squibb Co. | 2.17 | 1.49 | USD |
| 2014 | Bristol-Myers Squibb Co. | 2.46 | 1.45 | USD |
Gewinn je Aktie- Bristol-Myers Squibb
| 0.6 17 | 3.0 18 | 2.0 19 | -4.0 20 | 3.1 21 | 3.0 22 | 3.9 23 |
Umsatz je Aktie- Bristol-Myers Squibb
| 12.6 17 | 13.8 18 | 15.3 19 | 18.8 20 | 20.7 21 | 21.5 22 | 21.7 23 |
KGV- Bristol-Myers Squibb
| 101 17 | 17.3 18 | 32.0 19 | 20.0 21 | 24.4 22 | 13.3 23 |
Bristol-Myers Squibb Co.: Die Aktie (in USD)
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie berichtet | 0.61 | 3.01 | 2.01 | -3.99 | 3.12 | 2.95 | 3.86 |
| Gewinn je Aktie unverwässert | 0.61 | 3.01 | 2.02 | -3.99 | 3.15 | 2.97 | 3.88 |
| Gewinn je Aktie verwässert | 0.61 | 3.01 | 2.01 | -3.99 | 3.12 | 2.95 | 3.86 |
| Dividende pro Aktie | 1.57 | 1.61 | 1.68 | 1.84 | 2.01 | 2.19 | 2.31 |
| Gesamtdividendenausschüttung in Mio. | 2’577.00 | 2’613.00 | 2’679.00 | 4’075.00 | 4’396.00 | 4’634.00 | 4’744.00 |
Bristol-Myers Squibb Co.: Unternehmenskennzahlen (in USD)
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Umsatz je Aktie | 12.58 | 13.78 | 15.27 | 18.83 | 20.66 | 21.51 | 21.66 |
| KGV (Jahresendkurs, EPS unverwässert) | 100.53 | 17.30 | 31.95 | - | 20.01 | 24.40 | 13.29 |
| KGV (Jahresendkurs, EPS verwässert) | 100.53 | 17.30 | 31.95 | - | 20.01 | 24.40 | 13.29 |
| KGV (Jahresendkurs) | 100.53 | 17.30 | 31.95 | - | 20.01 | 24.40 | 13.29 |
| Dividendenrendite Jahresende in % | 2.56 | 3.10 | 2.62 | 2.97 | 3.22 | 3.04 | 4.50 |
| Eigenkapitalquote in % | 35.31 | 40.38 | 39.78 | 31.97 | 32.94 | 32.14 | 30.98 |
| Fremdkapitalquote in % | 64.69 | 59.62 | 60.22 | 68.03 | 67.06 | 67.86 | 69.02 |
Bristol-Myers Squibb Co.: GuV (in Mio. USD)
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Umsatzerlöse | 20’776.00 | 22’561.00 | 26’145.00 | 42’518.00 | 46’385.00 | 46’159.00 | 45’006.00 |
| Umsatzveränderung in % | 6.94 | 8.59 | 15.89 | 62.62 | 9.09 | -0.49 | -2.50 |
| Bruttoergebnis vom Umsatz | 15’087.00 | 16’075.00 | 17’250.00 | 21’700.00 | 26’761.00 | 26’490.00 | 25’357.00 |
| Bruttoergebnisveränderung in % | 4.08 | 6.55 | 7.31 | 25.80 | 23.32 | -1.01 | -4.28 |
| Operatives Ergebnis | 5’578.00 | 6’394.00 | 6’439.00 | 4’492.00 | 9’540.00 | 9’271.00 | 8’472.00 |
| Veränderung Operatives Ergebnis in % | 7.70 | 14.63 | 0.70 | -30.24 | 112.38 | -2.82 | -8.62 |
| Ergebnis vor Steuern | 5’131.00 | 5’968.00 | 4’975.00 | -6’871.00 | 8’098.00 | 7’713.00 | 8’440.00 |
| Veränderung Ergebnis vor Steuern in % | -13.25 | 16.31 | -16.64 | - | - | -4.75 | 9.43 |
| Ergebnis nach Steuer | 1’007.00 | 4’920.00 | 3’439.00 | -9’015.00 | 6’994.00 | 6’327.00 | 8’025.00 |
| Veränderung Ergebnis nach Steuer in % | -77.41 | 388.58 | -30.10 | - | - | -9.54 | 26.84 |
Bristol-Myers Squibb Co.: Bilanz (in Mio. USD)
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Gesamtverbindlichkeiten | 21’704 | 20’859 | 78’246 | 80’599 | 73’308 | 65’702 | 65’674 |
| Langzeit Gesamtverbindlichk. pro Aktie | 7.43 | 6.28 | 26.90 | 27.41 | 23.64 | 20.88 | 21.48 |
| Eigenkapital | 11’847 | 14’127 | 51’698 | 37’882 | 36’006 | 31’118 | 29’485 |
| Veränderung Eigenkapital in % | -27.42 | 19.50 | 267.74 | -26.70 | -4.96 | -13.59 | -5.25 |
| Bilanzsumme | 33’551 | 34’986 | 129’944 | 118’481 | 109’314 | 96’820 | 95’159 |
| Veränderung Bilanzsumme in % | -0.46 | 4.28 | 271.42 | -8.82 | -7.74 | -11.43 | -1.72 |
Bristol-Myers Squibb Co.: Sonstige Angaben (in USD)
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie (unverwässert) | 0.61 | 3.01 | 2.02 | -3.99 | 3.15 | 2.97 | 3.88 |
| Veränderung Gewinn je Aktie (unverwässert) in % | -77.05 | 392.14 | -33.05 | -297.94 | - | -5.67 | 30.58 |
| Gewinn je Aktie (verwässert) | 0.61 | 3.01 | 2.01 | -3.99 | 3.12 | 2.95 | 3.86 |
| Veränderung Gewinn je Aktie (verwässert) in % | -77.02 | 393.03 | -33.16 | -298.75 | - | -5.36 | 30.99 |
| Anzahl Mitarbeiter | 23’700 | 23’300 | 30’000 | 30’250 | 32’200 | 34’300 | 34’100 |
| Veränderung Anzahl Mitarbeiter in % | -5.20 | -1.69 | 28.76 | 0.83 | 6.45 | 6.52 | -0.58 |
Bristol-Myers Squibb Co. Termine
| Unternehmen | Event | Datum |
|---|---|---|
| Bristol-Myers Squibb Co. | Quartalszahlen | 06.02.2025 |
| Bristol-Myers Squibb Co. | Quartalszahlen | 24.04.2025 |
| Bristol-Myers Squibb Co. | Quartalszahlen | 31.07.2025 |
| Bristol-Myers Squibb Co. | Quartalszahlen | 30.10.2025 |
| Bristol-Myers Squibb Co. | Quartalszahlen | 29.01.2026 |
| Bristol-Myers Squibb Co. | Quartalszahlen | 23.04.2026 |
| Bristol-Myers Squibb Co. | Quartalszahlen | 23.07.2026 |
| Bristol-Myers Squibb Co. | Quartalszahlen | 29.10.2026 |
Bristol-Myers Squibb Co. vergangene Termine
| Terminart | Info | Datum |
|---|---|---|
| Quartalszahlen | Q3 2024 Earnings Release | 31.10.2024 |
| Quartalszahlen | Q2 2024 Earnings Release | 26.07.2024 |
| Hauptversammlung | Annual General Meeting | 07.05.2024 |
| Quartalszahlen | Q1 2024 Earnings Release | 25.04.2024 |
| Quartalszahlen | Q4 2023 Earnings Release | 02.02.2024 |
| Quartalszahlen | Q3 2023 Earnings Release | 26.10.2023 |
| Quartalszahlen | Q2 2023 Earnings Release | 27.07.2023 |
| Hauptversammlung | Annual General Meeting | 02.05.2023 |
| Quartalszahlen | Q1 2023 Earnings Release | 27.04.2023 |
| Quartalszahlen | Q4 2022 Earnings Release | 02.02.2023 |
| Quartalszahlen | Q3 2022 Earnings Release | 25.10.2022 |
| Quartalszahlen | Q2 2022 Earnings Release | 27.07.2022 |
| Hauptversammlung | Annual General Meeting | 03.05.2022 |
| Quartalszahlen | Q1 2022 Earnings Release | 29.04.2022 |
| Quartalszahlen | Q4 2021 Earnings Release | 04.02.2022 |
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 99.92 |
| The Vanguard Group, Inc. | 9.77 |
| Vanguard Group, Inc. (Subfiler) | 8.83 |
| State Street Corp. | 4.58 |
| Vanguard Total Stock Market ETF | 3.16 |
| Charles Schwab Investment Management, Inc. | 3.01 |
| BlackRock Fund Advisors | 2.92 |
| Vanguard 500 Index Fund | 2.65 |
| JPMorgan Investment Management, Inc. | 2.49 |
| Schwab US Dividend Equity ETF | 2.45 |
| BlackRock Institutional Trust Co. NA | 2.23 |
| Geode Capital Management LLC | 2.13 |
| Capital Research & Management Co. (International Investors) | 2.10 |
| Norges Bank (13F) | 1.61 |
| Fidelity 500 Index Fund | 1.23 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 30’000 | 30’250 | 32’200 | 34’300 | 34’100 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0.87 | 1.41 | 1.44 | 1.35 | 1.32 |
Bilanz (in Mio. USD) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 29’354 | 30’192 | 33’262 | 27’273 | 31’770 |
| Summe Anlagevermögen | 100’590 | 88’289 | 76’052 | 69’547 | 63’389 |
| Summe Aktiva | 129’944 | 118’481 | 109’314 | 96’820 | 95’159 |
Bilanz (in Mio. USD) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 47’538 | 51’673 | 45’596 | 40’717 | 41’464 |
| Summe Fremdkapital | 78’246 | 80’599 | 73’308 | 65’702 | 65’674 |
| Summe Eigenkapital | 51’698 | 37’882 | 36’006 | 31’118 | 29’485 |
| Summe Passiva | 129’944 | 118’481 | 109’314 | 96’820 | 95’159 |
Adresse
| Route 206 & Province Line Road, 08543 Princeton | |
| Telefon | +1 (609) 252-4621 |
| URL | http://www.bms.com |
Management
|
Abed Al-Nasser Odeh
Manager |
|
Adam Lenkowsky
Chief Commercialization Officer & Executive VP |
|
Amanda Poole
Chief Human Resources Officer & Executive VP |
|
Amy Fallone
Secretary |
|
Cari Gallman
Executive Vice President-Corporate Affairs |
|
Catalina Vargas
Chief Of Staff |
|
Christopher S. Boerner
Chairman & Chief Executive Officer |
|
Cynthia Piccirillo
Group Director |
|
David V. Elkins
Chief Financial Officer & Executive Vice President |
|
Deepak L. Bhatt
Independent Director |
|
Derica W. Rice
Independent Director |
|
Estelle Vester-Blokland
Senior VP-Global Medical Affairs |
|
Frank Incontrera
Director-Global Energy Services |
|
Greg Meyers
Chief Digital & Technology Officer |
|
Julia A. Haller
Independent Director |
|
Karen H. Vousden
Independent Director |
|
Kimberly McCutcheon Jablonski
Chief Compliance & Ethics Officer |
|
Krisztina Nemenyi
Head-Asia Pacific Global Regulatory Affairs |
|
Laura Hortas
Head-Corporate & Employee Communications |
|
Louis S. Schmukler
President-Global Product Development & Supply |
|
MARIA V LOPEZ BRESNAHAN
Vice President |
|
Manuel Hidalgo Medina
Independent Director |
|
Mark Rolfe
Senior Vice President |
|
Melissa Seymour
Chief Quality Officer |
|
Michael R. McMullen
Independent Director |
|
Monica Shaw
Senior Vice President-Major Markets |
|
Paula A. Price
Independent Director |
|
Peter J. Arduini
Independent Director |
|
Phil Holzer
Senior Vice President & Controller |
|
Phyllis R. Yale
Independent Director |
|
Robert M. Plenge
Chief Research Officer, Head-Research & EVP |
|
Samit Hirawat
Chief Medical Officer & EVP-Drug Development |
|
Sandra Leung
Executive Vice President & General Counsel |
|
Teresa M. Foy
Senior VP-Immuno Oncology & Cell Therapy |
|
Theodore Rapp Samuels
Lead Independent Director |
|
William Perhacs
Director-Global Energy & Sustainability Services |
|
Zack Newman
Associate Director-Global Sustainability Strategy |